

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UTILITY PATENT APPLICATION FOR

STEROL CARRIER PROTEIN-2 FROM THE MOSQUITO, *AEDES AEGYPTI*

Inventors : LAN, Que, residing at 5602 Hammersley Road, Madison,
Wisconsin 53711

KREBS, Kendall C., residing at W12207 State Road 89,
Waterloo, Wisconsin 53594

Assignee : Wisconsin Alumni Research Foundation

Entity : Small

Attorney Docket No. : 054030-0056

Total Claims, as filed : 11

Sheets of Sequence Listing : 2

Sheets of Drawings : 6

EXPRESS MAIL
Mailing Label Number EL 914961555 US

Date of Deposit April 13, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service
"Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above
and is addressed to the Mail Stop Patent Application, Commissioner For Patents, P.O. Box 1450,
Alexandria, VA 22313-1450.

Ruth Ellen Genac

(Typed or printed name of person mailing paper or fee)

Ruth Ellen Genac

(Signature of person mailing paper or fee)

Charles L. Leeck
Registration No. 50,343
GODFREY & KAHN, S.C.
780 North Water Street
Milwaukee, Wisconsin 53202
(414) 273-3500

MW798151_L.DOC

8. A method of identifying whether a compound is an agonist or antagonist of AeSCP-2 biological activity, comprising the steps of:

(a) incubating an AeSCP-2 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:3 or a biologically-active fragment thereof with a biological target in the presence of a compound; and

(b) measuring the ability of the compound to enhance or block the interaction between the AeSCP-2 polypeptide or fragment thereof and the biological target to thereby identify an agonist or antagonist effective in altering AeSCP-2 biological activity.

9. A method according to claim 8 wherein the biological target is cholesterol and the AeSCP-2 biological activity is cholesterol transport.

10. A method for identifying compounds which bind to or interact with an AeSCP-2 polypeptide or fragment thereof, comprising the steps of:

(a) contacting an AeSCP-2 polypeptide or fragment thereof with a compound to be screened under conditions to permit binding to or interaction between the compound and the AeSCP-2 polypeptide or fragment thereof to assess the binding to or interaction with the compound, such binding or interaction being associated with a detectable signal in response to the binding or interaction of the AeSCP-2 polypeptide or fragment thereof with the compound; and

(b) determining whether the compound binds to or interacts with the AeSCP-2 polypeptide or fragment thereof by detecting the presence or absence of the signal generated from the binding or interaction of the compound with the AeSCP-2 polypeptide or fragment thereof.